News for Healthier Living

Dana-Farber Phase 2 Trial Shows Deep and Lasting Responses to CAR T-Cell Therapy for High-Risk Smoldering Multiple Myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

April 20, 2026


April 21 2026

April 20 2026

April 19 2026

April 18 2026

April 17 2026

April 16 2026

April 15 2026

April 14 2026

April 13 2026

April 12 2026

April 11 2026

April 10 2026

April 9 2026

April 8 2026